Verastem Oncology develops oral small‑molecule inhibitors that target key nodes of the RAS/MAPK pathway—including RAF, MEK, and focal adhesion kinase—and integrates them into combination regimens to achieve durable pathway suppression in RAS/MAPK‑driven cancers. Its FDA‑approved combination for KRAS‑mutant low‑grade serous ovarian cancer validates the approach, and its biomarker‑guided pipeline expands these therapies across multiple tumor types.
Funding
Funding not disclosed
Founders
Product
Problem
A substantial proportion of solid tumors harbor alterations in the RAS/MAPK signaling cascade, leading to aggressive disease phenotypes, high recurrence rates, and limited effective therapeutic options. Patients with KRAS‑mutant low‑grade serous ovarian cancer, in particular, experience poor outcomes after standard treatments.
Solution
Verastem Oncology creates novel small‑molecule inhibitors that directly target key nodes of the RAS/MAPK pathway, such as RAF, MEK, and focal adhesion kinase (FAK). By integrating these agents into rational combination regimens, the company seeks to achieve durable pathway suppression and overcome resistance mechanisms. An FDA‑approved combination therapy for KRAS‑mutant recurrent low‑grade serous ovarian cancer demonstrates the clinical viability of this approach. Ongoing clinical programs evaluate additional inhibitors and combination strategies across a broad spectrum of RAS/MAPK‑driven malignancies, leveraging biomarker‑guided patient selection to maximize therapeutic benefit.
Target Audience
The primary customers are oncology clinicians and clinical trial investigators treating patients with RAS/MAPK‑driven cancers, as well as pharmaceutical partners seeking to co‑develop or license pathway‑targeted therapies.
Features
- Avutometinib (VS‑6766): a dual RAF/MEK clamp that simultaneously engages both kinases to achieve sustained pathway inhibition.
- Defactinib: a selective focal adhesion kinase inhibitor designed to disrupt tumor‑cell adhesion and signaling crosstalk.
- Combination‑therapy platform that pairs pathway‑targeted agents with standard chemotherapies, immunotherapies, or other targeted drugs to enhance efficacy and delay resistance.
- Biomarker‑driven clinical trial design using genomic profiling (e.g., KRAS, NRAS, BRAF mutations) to enroll patients most likely to respond.
- Oral administration of all small‑molecule candidates, facilitating outpatient treatment and patient compliance.
- Robust pipeline of Phase 1/2 studies across multiple tumor types, supported by strategic collaborations with academic centers and pharmaceutical partners.
- Integrated pharmacokinetic/pharmacodynamic (PK/PD) modeling to optimize dosing schedules and combination ratios.
- Regulatory‑focused development strategy that aligns preclinical data with FDA guidance for accelerated approval pathways.